首页> 外文OA文献 >IMPORT Trial Management Group. Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom.
【2h】

IMPORT Trial Management Group. Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom.

机译:进口试验管理组。 ImpORT HIGH试验(CRUK / 06/003)对英国乳房放射治疗实践的临床影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE:IMPORT HIGH is a multicentre randomized UK trial testing dose-escalated intensity-modulated radiotherapy (IMRT) after tumour excision in females with early breast cancer and higher than average local recurrence risk. A survey was carried out to investigate the impact of this trial on the adoption of advanced breast radiotherapy (RT) techniques in the UK.METHODS:A questionnaire was sent to all 26 IMPORT HIGH recruiting RT centres to determine whether the trial has influenced non-trial breast RT techniques in terms of volume delineation, dosimetry, treatment delivery and verification. In order to compare the clinical practice of breast RT between IMPORT HIGH and non–IMPORT HIGH centres, parts of the Royal College of Radiologists (RCR) breast RT audit result were used in this study.RESULTS:26/26 participating centres completed the questionnaire. After joining the trial, the number of centres routinely using tumour bed clips to guide whole-breast RT rose from 5 (19%) to 21 (81%). 20/26 (77%) centres now contour target volumes and organs at risk (OARs) in some or all patients compared with 14 (54%) before the trial. 14/26 (54%) centres offer inverse-planned IMRT for selected non-trial patients with breast cancer, and 10/14 (71%) have adopted the IMPORT HIGH trial protocol for target volume and OARs dose constraints. Only 2/26 (8%) centres used clip information routinely for breast treatment verification prior to IMPORT HIGH, a minority that has since risen to 7/26 (27%). Data on 1386 patients was included from the RCR audit. This suggested that more cases from IMPORT HIGH centres had surgical clips implanted (83 vs 67%), were treated using CT guided planning with full three-dimensional dose compensation (100 vs 75%), and were treated with photon boost RT (30 vs 8%).CONCLUSION:The study suggests that participation in the IMPORT HIGH trial has played an important part in providing the guidance and support networks needed for the safe integration of advanced RT techniques, where appropriate, as a standard of care for breast cancer patients treated at participating cancer centres.ADVANCES IN KNOWLEDGE:We investigated the impact of the IMPORT HIGH trial on the adoption of advanced breast RT techniques in the UK and the trial has influenced non-trial breast RT techniques in terms of volume delineation, dosimetry, treatment delivery and verification.
机译:目的:IMPORT HIGH是一项多中心随机英国试验,在早期乳腺癌且局部复发风险高于平均水平的女性中,进行肿瘤切除后剂量递增的调强放射治疗(IMRT)。进行了一项调查,以调查该试验对英国采用先进的乳腺放疗(RT)技术的影响。方法:向所有26个IMPORT HIGH招募的RT中心发送了一份问卷,以确定该试验是否影响了非乳腺放疗。在体积描绘,剂量测定,治疗提供和验证方面试用乳房RT技术。为了比较IMPORT HIGH和非IMPORT HIGH中心之间的乳腺癌放疗的临床实践,本研究使用了皇家放射学院(RCR)的部分乳腺癌放疗审核结果。结果:26/26个参与中心完成了问卷调查。加入试验后,常规使用肿瘤床夹引导全乳放疗的中心从5个(19%)增加到21个(81%)。现在,有20/26(77%)个中心勾勒出部分或全部患者的目标体积和危险器官(OARs)的轮廓,而试验前只有14个(54%)。 14/26(54%)的研究中心为某些非试验性乳腺癌患者提供了反向计划的IMRT,而10/14(71%)的研究机构针对目标量和OAR剂量限制采用了IMPORT HIGH试验方案。只有2/26(8%)个中心在IMPORT HIGH之前常规使用剪辑信息来进行乳房治疗验证,此后这一比例上升到7/26(27%)。 RCR审核中包括了1386名患者的数据。这表明更多来自IMPORT HIGH中心的病例植入了手术夹(83%对67%),接受了CT指导计划的全三维剂量补偿治疗(100%对75%),并接受了光子增强RT治疗(30对8%)。结论:该研究表明,参加IMPORT HIGH试验在提供指导和支持网络方面发挥了重要作用,在适当的情况下,这些指导和支持网络可安全整合先进的RT技术,作为乳腺癌患者的治疗标准知识的进展:我们调查了IMPORT HIGH试验对英国采用先进的乳腺RT技术的影响,该试验在容积描画,剂量测定,治疗方面影响了非试验性乳腺RT技术。交付和验证。

著录项

  • 作者

    Kirwan, Cliona;

  • 作者单位
  • 年度 2015
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号